FDA/Industry Manufacturing Approach Is “Suboptimal” – CDER’s Woodcock
This article was originally published in The Tan Sheet
Executive Summary
FDA is ready to change the current model of manufacturing oversight and enforcement, Center for Drug Evaluation & Research Director Janet Woodcock, MD, indicated during the recent Lehman Brothers Global Healthcare Conference in Orlando